Article info
PDFOesophagus
A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
- Correspondence to Dr C Keywood, Addex Pharma SA, Plan-les-Ouates, CH-1228 Switzerland; charlotte.keywood{at}addexpharma.com
Citation
A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease
Publication history
- Revised April 19, 2009
- Accepted April 21, 2009
- First published May 20, 2009.
Online issue publication
October 26, 2017
Web only appendix 58:9;1192
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Keywood et al 2009 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.